Altana advises ONXEO, a company listed on Compartment B of Euronext Paris and on the Copenhagen NASDAQ, in the execution of a binding agreement to acquire DNA Therapeutics.

DNA Therapeutics is a biopharmaceutical company, with first-in-class therapeutic molecule in the cancer treatment. This new acquisition allows ONXEO to expand its pipeline and opens new opportunities in new orphan oncology indications.

The acquisition of DNA Therapeutics demonstrates once again ONXEO’s commitment to be a leader in the development of new drugs in the orphan oncology treatments and ranks the Company at the forefront of scientific research with the potential to generate significant value for its stakeholders.

According to the terms of the agreement; ONXEO will acquire DNA Therapeutics for an upfront payment of € 1.7 million payable at closing in ONXEO common shares. An additional payment will be made in an amount of € 1 million payable in ONXEO shares or in cash at ONXEO’s discretion, upon successful initiation of a Phase II trial in one of the selected indications. Finally, royalty payments on future commercial sales will be payable up to € 25 million per indication.

ALTANA had previously advised ONXEO (formerly BIOALLIANCE PHARMA) in its cross-border merger with the Danish company TOPOTARGET in 2014. This merger was the first-ever cross border merger of a French listed company with a listed company of a different nationality under the 2005 merger Directive.

– Acquirer: ONXEO

– Legal advisors: ALTANA (Jean-Nicolas Soret / Fabien Pouchot)

– Tax advisors: ARSENE TAXAND (Olivier Vergniolle / Marion Dervieux)

– Financial advisors: ERNST & YOUNG (Jérôme Vailland / Mehdi Houkari)

– Seller: DNA Therapeutics Shareholders

– Legal advisors: HBC Avocats (Erwan Cossé / Laurent Comperot)